Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors.
East
Mark A
MA
Division of Cardiology, Department of Medicine, Duke University and Durham Veteran's Administration Medical Center, Durham, North Carolina 27705, USA.
Landis
Dawn I
DI
Thompson
Michael A
MA
Annex
Brian H
BH
D000925:Anticoagulants / Q000008:administration & dosage*; D006328:Cardiac Catheterization; D003327:Coronary Disease / Q000378:metabolism / Q000628:therapy; D016228:Endothelial Growth Factors / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000925:Anticoagulants; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D006493:Heparin